HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: FSMA Rules Proposed | One-Step Exclusivity | Early At CHPA | EU Clears NovaTears

This article was originally published in The Tan Sheet

Executive Summary

FSMA auditing, supplier verification rules proposed; Plan B One-Step gets OTC exclusivity until 2016; Early joins CHPA as VP, CFO; Novaliq’s NovaTears Gains EU approval; and Senate bill boosts NIH appropriation.

You may also be interested in...



Plan B One-Step OTC Proposal Leaves Plaintiffs, Judge Korman Wary

The Center for Reproductive Rights and other plaintiffs suing FDA say the agency’s plan to approve only Teva’s Plan B One-Step for universal OTC sales, but not less-expensive generic emergency contraceptives, would not provide sufficient access for all women.

FSMA Supplier Verification Rule Close, But Third-Party Accreditation Stalls

FDA Center for Food Safety and Applied Nutrition Director Michael Landa says rules for preventive controls for human food and the foreign supplier verification program are “in the final stages of review.” However, the rule for accreditation of third-party inspectors is stalled.

Abbott Readying Vildagliptin ER In India Amid Price Competition

Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.

Topics

Related Companies

UsernamePublicRestriction

Register

RS124404

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel